JWH-018 (1-pentyl-three-(1-naphthyl)indole) or AM-678 is an analgesic chemical that belongs to the naphthoylindole circle of relatives. It functions as a complete agonist at the CB1 and CB2 cannabinoid receptors, with a small amount of selectivity for the CB2 receptor. It has effects in animals identical to those of tetrahydrocannabinol (THC), a cannabinoid naturally found in cannabis. As a result, it is used in synthetic cannabis products, referred to as “incense blends”, in some countries and can be purchased legally there.
This chemical compound is an analgesic treatment because it acts as a full agonist at the CB1 and CB2 cannabinoid receptors. The analgesic effects of cannabinoid ligands, which are mediated by CB1 receptors, are properly installed in the treatment of neuropathic pain and cancer aches and arthritis pain.
These compounds function by imitating the naturally occurring endocannabinoid hormones in the body, such as 2-AG and anandamide (AEA), that is biologically active and may either exacerbate or inhibit nerve signalling. Because the reason behind chronic pain states is not well understood, additional research and development must be completed before the therapeutic potential of this class of biologic compounds can be determined.
At this point, at least one instance of reliance on JWH-018 has been reported by various forms of media. The individual drank JWH-018 daily for eight months. The withdrawal symptoms were significantly more severe than those experienced from reliance on cannabis. It has been demonstrated that injection of JWH-018 causes dramatic changes in the density of CB1 receptors. This, in turn, causes desensitization to the effects of JWH-018 more quickly than is the case with comparable cannabinoids.
The cause of death of a college basketball player from South Carolina was determined to be “drug toxicity and organ failure” on October 15, 2011, by the Anderson County coroner Greg Shore. JWH-018 was the causal agent in this case.
The city of Anderson, South Carolina, eventually distributed an email with a date of November 4, 2011, about the investigation of the matter. After several requests made by the media to view the information were turned down, on December 16, 2011, following the Freedom of Information Act, the information was finally made public.
JWH-018 and many synthetic cannabinoids are full agonists at CB1 receptors, in contrast to THC, which is just a partial agonist at these receptors. It has been demonstrated that THC inhibits the neurotransmission of GABA receptors in the brain via various mechanisms. Because it inhibits GABA neurotransmission more effectively than THC, JWH-018 is suspected of being the cause of seizures and convulsions in a few isolated cases (typically involving JWH users who don’t use the substance regularly). This has led to the belief that the substance is responsible for intense anxiety and agitation. When used in excessive amounts, cannabinoid receptor full agonists may potentially present the user with a number of significant hazards. [
There have been reports of various negative consequences, both physically and mentally, associated with the usage of JWH-018. One look at the reported cases of psychotic relapses and tension symptoms that occurred in individuals with intellectual illness who were being properly treated after they inhaled JWH-018. It has been recommended that people with risk factors for psychotic illnesses, such as a history of psychosis in themselves or a history of psychosis in their family, refrain from using JWH-018 and other synthetic cannabinoids. This recommendation was made due to concerns about the ability of JWH-018 and other synthetic cannabinoids to cause psychosis in susceptible individuals.
Store in a cool place away from sunlight and try to use the powder before its expiry date